Elevance Health Reports Q2 2026 Revenue Increase but Decline in Net Income

Elevance Health, Inc. reported its financial results for the second quarter and first half of 2026, revealing a slight increase in total revenues but a decline in net income compared to the same periods in 2025. For the three months ended June 30, 2026, the company generated total revenues of $50.5 billion, a 1.4% increase from $49.8 billion in the prior year. However, net income fell to $1.5 billion, down 16.6% from $1.7 billion in the same quarter of 2025. For the six-month period, total revenues reached $100.7 billion, up 2.0% from $98.7 billion, while net income decreased to $3.2 billion from $3.9 billion.

The company's operating revenue for the second quarter was $49.8 billion, reflecting a 0.8% increase year-over-year, primarily driven by premium rate increases in the Health Benefits segment and growth in CarelonRx product revenues. However, this growth was partially offset by membership attrition, particularly in the Medicaid and Medicare Advantage segments. The total medical membership decreased by 1.5% year-over-year, attributed to eligibility redeterminations in Medicaid and declines in Medicare Advantage and Employer Group Risk-Based memberships.

Elevance Health has also initiated a strategic transformation program aimed at streamlining operations and enhancing technology use, including artificial intelligence. This program is expected to involve workforce reductions and realignments, with costs associated with the initiative amounting to $129 million in the first half of 2026. The company reported an operating cash flow of $6.2 billion for the first half of 2026, significantly higher than the $3.1 billion reported in the same period of 2025, indicating improved working capital management.

In terms of market performance, Elevance Health served approximately 44.9 million medical members as of June 30, 2026. The company continues to expand its services, including pharmacy and healthcare-related services through its CarelonRx and Carelon Services segments. The company’s debt-to-capital ratio improved to 40.8% from 42.1% at the end of 2025, reflecting a strong financial position. Looking ahead, Elevance Health anticipates continued challenges in the healthcare landscape, including regulatory changes and competitive pressures, but remains focused on leveraging its operational efficiencies and strategic initiatives to drive future growth.